Results 71 to 80 of about 54,164 (265)

The Bacterial Gut Microbiota of Adult Patients Infected, Colonized or Noncolonized by Clostridioides difficile

Microorganisms, 2020
Gut microbiota composition in patients with Clostridioides difficile colonization is not well investigated. We aimed to identify bacterial signatures associated with resistance and susceptibility to C.
Monique J. T. Crobach, Quinten R. Ducarmon, Elisabeth M. Terveer, Celine Harmanus, Ingrid M. J. G. Sanders, Kees M. Verduin, Ed J. Kuijper, Romy D. Zwittink   +7 more
doaj   +1 more source

Diagnosing Clostridioides difficile infections with molecular diagnostics: multicenter evaluation of revogene C. difficile assay [PDF]

, 2020
Clostridioides difficile infections are a significant threat to our healthcare system, and rapid and accurate diagnostics are crucial to implement the necessary infection prevention and control measurements.
Altwegg M., Arnold M., Barbut F., Berlinger L., Couturier J., Delmee M., Dirani G., Gateau C., Hallet E., Op den Buijs I., Roymans R., Sambri V., Steiner S., van Broeck J., van de Bovenkamp J., Zannoli S., Zumoberhaus A.   +16 more
core   +2 more sources

Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice [PDF]

, 2023
INTRODUCTION Faecal microbiota transplantation (FMT) is an established therapy for recurrent C. difficile infection, and recent studies have reported encouraging results of FMT in patients with ulcerative colitis.
Burri, Emanuel, Décosterd, Natalie, Galperine, Tatiana, Hrúz, Petr, Juillerat, Pascal, Matter, Christoph, Rossier, Laura, Schoepfer, Alain, Seibold, Frank, Vavricka, Stephan R, Zahnd, Nadine   +10 more
core   +1 more source

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies

Gut microbes, 2023
Human gut microbiota are critical to both the development of and recovery from Clostridioides difficile infection (CDI). Antibiotics are the mainstay of CDI treatment, yet inherently cause further imbalances in the gut microbiota, termed dysbiosis ...
A. Gonzales-Luna, T. Carlson, K. Garey
semanticscholar   +1 more source

Clostridioides difficile co-infection with Enterohemorrhagic Escherichia coli (EHEC)—a potentially fatal combination

IDCases, 2020
There has been a significant increase in hospital and community acquired Clostridioides difficile infection in the past decade. In addition to CDI, the rate of infection with enterohemorrhagic Escherichia coli (EHEC) has also increased by 28% in United ...
Farah Deshmukh, Upasana Agrawal, Nancy Merrell   +2 more
doaj   +1 more source

Reduction in Health Care Facility–Onset Clostridioides difficile Infection: A Quality Improvement Initiative

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021
Objective: To reduce health care facility–onset (HCFO) Clostridioides difficile infection (CDI) incidence by improving diagnostic stewardship and reducing the inappropriate testing of C difficile assays.
Himesh B. Zaver, MD, Varun P. Moktan, MD, Eugene P. Harper, MD, Aman Bali, MD, Ayan Nasir, MD, Carla Foulks, MD, Justin Kuhlman, MD, Max Green, MD, Gillian A. Algan, BS, Heather C. Parth, MPH, Melody Wu-Ballis, BS, Sandra DiCicco, BS, Brenda T. Smith, BS, Ronald N. Owen, BS, Lorraine S. Mai, BS, Sarah L. Spiros, BS, John Griffis, BS, Daphne T. Ramsey Walker, BS, D. Jane Hata, PhD, Justin M. Oring, DO, Harry R. Powers, MD, Wendelyn Bosch, MD   +21 more
doaj   +1 more source

My Treatment Approach to Clostridioides difficile Infection [PDF]

Mayo Clinic Proceedings, 2021
Clostridioides difficile infection is the most common cause of infectious diarrhea in hospitals with an increasing incidence in the community. Clinical presentation of C difficile infection ranges from diarrhea manageable in the outpatient setting to fulminant infection requiring intensive care admission.
openaire   +2 more sources

Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

Therapeutic Advances in Gastroenterology, 2023
Background: Microbiota-based treatments reduce the incidence of recurrent Clostridioides difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient access and protect public health have been limited.
Christine Lee, T. Louie, Lindy L. Bancke, B. Guthmueller, Adam J Harvey, P. Feuerstadt, S. Khanna, R. Orenstein, E. Dubberke   +8 more
semanticscholar   +1 more source

Clostridioides difficile Infection Dysregulates Brain Dopamine Metabolism

Microbiology Spectrum, 2022
The gut-brain axis is thought to play a significant role in the development and manifestation of neurologic diseases. This study reports significant alterations in the brain dopamine metabolism in mice infected with C. difficile , an important pathogen that overgrows in the gut after prolonged antibiotic therapy ...
Akhil A. Vinithakumari, Piyush Padhi, Belen Hernandez, Susanne Je-Han Lin, Aaron Dunkerson-Kurzhumov, Lucas Showman, Matthew Breitzman, Caroline Stokes, Yousuf Sulaiman, Chandra Tangudu, Deepa A. Kuttappan, Muhammed S. Muyyarikkandy, Auriel A. Willette, Gregory J. Phillips, Vellareddy Anantharam, Ann Perera, Brett A. Sponseller, Anumantha Kanthasamy, Shankumar Mooyottu   +18 more
openaire   +3 more sources

Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives

Gut Pathogens, 2023
Clostridioides difficile , which causes life-threatening diarrheal disease, is considered an urgent threat to healthcare setting worldwide. The current standards of care solely rely on conventional antibiotic treatment, however, there is a risk of ...
H. Raeisi, M. Noori, M. Azimirad, S. Mohebbi, H. Asadzadeh Aghdaei, Abbas Yadegar, M. Zali   +6 more
semanticscholar   +1 more source